On March 16, 2023, Pfizer Inc announced that it has received a shareholder proposal from Oxfam America Inc, requesting the Company to commission a third-party report to analyzing the feasibility of promptly transferring intellectual property (IP) and technical knowledge to facilitate the production of COVID-19 vaccine doses by additional qualified manufacturers located in low- and middle-income countries, as defined by the World Bank. In addition, the Company urged the shareholders to vote against the proposal at the annual meeting of shareholders scheduled to be held on April 27, 2023.